The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Eisai’s Lenvima Gains Positive Opinion from CHMP
March 31, 2015
- Taisho Partners with Teijin to Comarket Patch Formulation Containing S-Flurbiprofen
March 31, 2015
- Hisamitsu to Rejuvenate Management with Nakatomi Junior as President
March 30, 2015
- Ichiro Otsuka Becomes Chairman of Otsuka Holdings
March 30, 2015
- Pfizer Looking for Drug Discovery Partnerships with Domestic Drug Makers
March 30, 2015
- Genzyme Japan Receives Approval for Japan’s 1st Oral Gaucher’s Disease Treatment Cerdelga
March 30, 2015
- E Keppra Filed for Generalized Tonic-Clonic Seizures: Otsuka, UCB Japan
March 30, 2015
- Takeda Seeks Japan Approval for Single-Packs Containing Takecab for H. pylori Eradication
March 27, 2015
- Sovaldi, Oral, Interferon-Free Treatment, Approved for Chronic HCV Infection in Japan: Gilead Sciences
March 27, 2015
- Xtandi Significantly Extends OS, Lowers Risk of Death by 23%
March 26, 2015
- Santen Ups FY2014 Financial Outlook on Merck Asset Acquisition
March 26, 2015
- Sun Pharma Completes Merger with Ranbaxy; Daiichi Sankyo Owns 9% Share in Combined Firm
March 26, 2015
- Yoshiki Ito to Lead Merged Entity of Allergan, Actavis in Japan
March 25, 2015
- 3-Bracket Pricing Rule for Generics Should Be Defended: Sawai Chairman
March 25, 2015
- Takeda to Collaborate with ImmunoGen for ADC Technology
March 25, 2015
- Investigational Duchenne Muscular Dystrophy Drug Shows Favorable Results: Nippon Shinyaku, NCNP
March 25, 2015
- AZ Looks to Lead Industry in Immuno-Oncology Arena: Oncology Head
March 24, 2015
- Opdivo Wins South Korean Approval: Ono
March 24, 2015
- Takeda to Set Up Japan Oncology, Vaccine Business Units as Part of Corporate Reorganization
March 24, 2015
- Merck KGaA Gauging Regional Priorities for PD-L1 Inhibitor Development: Exec
March 24, 2015
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…